Outsource organoid production to the experts!

Get the large numbers of high-quality, low-variability organoids you need in a convenient assay-ready format. 

 

Manual organoid culture methods can be a time-consuming, inefficient and expensive process that only produce small numbers of inconsistent organoids. This can act as a major bottleneck in research and screening programs using these cell models. 

 

By outsourcing organoid production to us, you can obtain upwards of 10 million assay-ready, quality assured organoids - freeing up resources, streamlining your workflows, and enabling you to perform large-scale organoid screens, 

 

 

Cell-Gn-1

10M+ consistent organoids

Perform high-throughput and repeat organoid assays involving many millions of organoids

Handshake-Gn

Outsource to the experts

Free up your scientists to focus on their research, rather than organoid expansion

Scientific-team-Gn

Assay-ready organoids

Our organoids are conveniently available in frozen vials, ready for immediate use whenever they're needed

Protocols-Gn-1

Quality controlled

A rigorous - and customizable - QC process gives you confidence in your organoid models - and your data

Contact our expert team today to accelerate your organoid research 

How can we help?

Join clients from major pharmaceutical corporations, contract-research organizations and biotech companies who have benefitted from our organoid expansion service. 

Remember to sign up for our mailing list to stay up to date with the latest 3D biology news, applications, and updates. 

 

Get In Touch

3D Ready Organoid Expansion Service

Bioprocess-grown PDOs at scale with validation and quality assurance

Industrial manufacturing of human-derived 3D organoids is now possible with our 3D Ready™ Organoid Expansion Service. This proprietary bioreactor and patent-pending bioprocess technology offers large scale expansion of organoids, by generating high volumes of reproducible organoid models.

Organoids can model complex in vivo processes in vitro. Using human materials, such as Patient-Derived Organoids (PDOs), earlier in research and development provides biotech and pharma with patient-centric models that give more applicable results, potentially enabling a reduction in the use of animals and animal tissues
Picture1-1

*Price, time to deliver, and specifications will vary based on mutually agreed technical requirements. Solution requirements may cause adjustment to standard performance.